Cargando…

A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy

BACKGROUND: Women with endometrial or ovarian cancer experience a variety of symptoms during chemotherapy. Patient-Reported outcomes (PROs) can provide insight into the symptoms they experience. A PRO tool tailored to this patient population can help accurately monitor adverse events and manage symp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christiansen, Mille Guldager, Pappot, Helle, Jensen, Pernille Tine, Mirza, Mansoor Raza, Jarden, Mary, Piil, Karin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354345/ https://www.ncbi.nlm.nih.gov/pubmed/37462855 http://dx.doi.org/10.1186/s41687-023-00611-w

Ejemplares similares

Patient perspectives and experiences of the rapid implementation of digital consultations during COVID-19 — a qualitative study among women with gynecological cancer
por: Christiansen, Mille Guldager, et al.
Publicado: (2021)

Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients
por: Baeksted, Christina, et al.
Publicado: (2017)

Electronic Games for Facilitating Social Interaction Between Parents With Cancer and Their Children During Hospitalization: Interdisciplinary Game Development
por: Piil, Karin, et al.
Publicado: (2021)

Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE(®) to Provide Two Distinct and Complementary Perspectives
por: Minasian, Lori M, et al.
Publicado: (2022)

Current trends in patient and public involvement in cancer research: A systematic review
por: Pii, Kathrine Hoffmann, et al.
Publicado: (2018)

Patient involvement in research priorities (PIRE): a study protocol
por: Piil, Karin, et al.
Publicado: (2016)

A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies
por: Regnault, Antoine, et al.
Publicado: (2023)

Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period
por: Lee, M. K., et al.
Publicado: (2023)

Research involvement and engagement of adolescent and young adults in a cancer trajectory: a 5-year experience from a patient support facility at a university hospital
por: Pappot, Helle, et al.
Publicado: (2023)

Development of a keyword library for capturing PRO-CTCAE-focused “symptom talk” in oncology conversations
por: Durieux, Brigitte N, et al.
Publicado: (2023)

Patient and public involvement in Nordic healthcare research: a scoping review of contemporary practice
por: Dengsø, Kristine Elberg, et al.
Publicado: (2023)

Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
por: Wang, Tian Qi, et al.
Publicado: (2018)

Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)
por: Caminiti, Caterina, et al.
Publicado: (2022)

Decisional needs of patients with recurrent high-grade glioma and their families
por: Sorensen von Essen, Helle, et al.
Publicado: (2022)

Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Schroeder, Kristin M., et al.
Publicado: (2023)

Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure
por: Feldman, E., et al.
Publicado: (2023)

Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers
por: Günther, Maximilian, et al.
Publicado: (2023)

Efficacy of the PRO-CTCAE mobile application for improving patient participation in symptom management during cancer treatment: a randomized controlled trial
por: Lee, Mangyeong, et al.
Publicado: (2023)

The use of and adherence to CTCAE v3.0 in cancer clinical trial publications
por: Zhang, Sheng, et al.
Publicado: (2016)

Controlled rehabilitative and supportive care intervention trials in patients with high-grade gliomas and their caregivers: a systematic review
por: Piil, K, et al.
Publicado: (2016)

Family caregiver ambassador support for caregivers of patients with newly diagnosed hematological cancer: a feasibility study
por: Husted Nielsen, Iben, et al.
Publicado: (2022)

Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
por: Miyaji, Tempei, et al.
Publicado: (2017)

Dutch translation and linguistic validation of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)
por: Veldhuijzen, Evalien, et al.
Publicado: (2020)

Score equivalence of paper-, tablet-, and interactive voice response system-based versions of PROMIS, PRO-CTCAE, and numerical rating scales among cancer patients
por: Lee, Minji K., et al.
Publicado: (2021)

Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
por: Mazza, Gina L., et al.
Publicado: (2021)

Linguistic validation of the simplified Chinese version of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™)
por: KKF, Cheng, et al.
Publicado: (2020)

Correction to: Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
por: Mazza, Gina L., et al.
Publicado: (2021)

A longitudinal, qualitative and quantitative exploration of daily life and need for rehabilitation among patients with high-grade gliomas and their caregivers
por: Piil, K, et al.
Publicado: (2013)

P1723: A FEASIBILITY STUDY OF PEER SUPPORT IN FAMILY CAREGIVERS OF PATIENTS NEWLY DIAGNOSED WITH HEMATOLOGIC MALIGNANCY
por: Nielsen, I. H., et al.
Publicado: (2022)

Patients’ experience of communication and handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy
por: Bæksted, Christina Witt, et al.
Publicado: (2019)

Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer
por: Kowalchuk, Roman O., et al.
Publicado: (2021)

P1730: IMPLEMENTATION OF PRO-CTCAE QUESTIONNAIRE IN PROM PROGRAM COLLECTS DIFFERENT ADVERSE EVENTS PROFILE THAN PHYSICIANS AND REDUCE UNSCHEDULED HEALTHCARE IN PATIENTS WITH LYMPHOMA RECEIVING IV THERAPY
por: RAMOS, S., et al.
Publicado: (2022)

OCCUPATIONAL AND PHYSIOTHERAPY MODALITIES USED TO SUPPORT INTERDISCIPLINARY REHABILITATION AFTER CONCUSSION: A SCOPING REVIEW
por: NABSEN MARWAA, Mille, et al.
Publicado: (2023)

The development of medical infographics to raise symptom awareness and promote communication to patients with cancer: A co-creation study
por: Piil, Karin, et al.
Publicado: (2023)

THU513 Are Endocrinologists Using CTCAE Grading System For Endocrine Side Effects Of Cancer Treatment With Immune Checkpoint Inhibitors?
por: Arnouk, Nelly, et al.
Publicado: (2023)

Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?
por: Mahdi, Haider, et al.
Publicado: (2023)

The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events
por: Kawaguchi, Takashi, et al.
Publicado: (2018)

The long-term course of fatigue following breast cancer diagnosis
por: Biering, Karin, et al.
Publicado: (2020)

Optimal Systemic Treatment of Advanced Bladder Cancer—A Moving Target
por: Pappot, Helle, et al.
Publicado: (2020)

Optimal Systemic Treatment of Advanced Bladder Cancer Calls for a Multidisciplinary Approach
por: Pappot, Helle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_strp50c34veipeq6s0rdlgnpcg